Vir Biotechnology (VIR) Set to Announce Earnings on Wednesday

Vir Biotechnology (NASDAQ:VIR) is projected to announce its Q3 2026 results after the market closes on Wednesday, November 4th. Analysts expect the company to announce earnings of ($0.7393) per share and revenue of $0.86 million for the quarter. Interested persons may review the information on the company’s upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Wednesday, November 4, 2026 at 4:30 PM ET.

Vir Biotechnology (NASDAQ:VIR) last issued its earnings results on Wednesday, August 5th. The company reported $0.47 EPS for the quarter, topping the consensus estimate of $0.33 by $0.14. The firm had revenue of $238.95 million during the quarter, compared to the consensus estimate of $135.88 million. During the same period last year, the business earned ($0.80) earnings per share. The firm’s revenue for the quarter was up 19582.5% compared to the same quarter last year. On average, analysts expect Vir Biotechnology to post ($1.84) EPS for the current fiscal year and ($2.61) EPS for the next fiscal year.

Vir Biotechnology Price Performance

VIR opened at $11.57 on Wednesday. The company has a market capitalization of $1.96 billion, a P/E ratio of -6.22 and a beta of 1.59. The firm’s fifty day moving average price is $10.81 and its two-hundred day moving average price is $9.40. Vir Biotechnology has a fifty-two week low of $4.82 and a fifty-two week high of $12.00.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on VIR shares. HC Wainwright raised their price objective on shares of Vir Biotechnology from $20.00 to $22.00 and gave the stock a “buy” rating in a report on Wednesday, October 7th. Weiss Ratings reissued a “sell (d-)” rating on shares of Vir Biotechnology in a research note on Friday, October 2nd. Raymond James Financial reissued a “strong-buy” rating on shares of Vir Biotechnology in a research note on Monday, September 28th. Wall Street Zen raised shares of Vir Biotechnology from a “sell” rating to a “hold” rating in a research report on Saturday, August 8th. Finally, Zacks Research cut shares of Vir Biotechnology from a “hold” rating to a “strong sell” rating in a research note on Tuesday, October 6th. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and two have issued a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $21.86.

About Vir Biotechnology

Vir Biotechnology, Inc is a clinical-stage immunology company focused on developing medicines to prevent and treat serious infectious diseases and other immune-related conditions. The company uses antibody engineering, immunologic approaches and other technologies to identify and advance therapies designed to harness or modify the immune system.

Vir’s research and development programs have included treatments and vaccines for hepatitis B, human immunodeficiency virus (HIV), influenza and other infectious diseases.